Moderna (NASDAQ:MRNA) has outperformed the market over the past 5 years by 23.65% on an annualized basis producing an average annual return of 35.34%. Currently, Moderna has a market capitalization of $42.89 billion.
Buying $1000 In MRNA: If an ...
Moderna (NASDAQ:MRNA) has outperformed the market over the past 5 years by 23.65% on an annualized basis producing an average annual return of 35.34%. Currently, Moderna has a market capitalization of $42.89 billion.
Buying $1000 In MRNA: If an ...
Market Wire News is a media platform, the information on this page was provided by Benzinga via Quote Media. Read our full disclaimer.
When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
News, Short Squeeze, Breakout and More Instantly...
Moderna, Inc. (NASDAQ: MRNA) announced that it has submitted an application to the FDA seeking approval of its Spikevax 2024-2025 formula, tar...
On CNBC's “Halftime Report Final Trades,” Liz Young of SoFi named The Energy Select Sector SPDR Fund (NYSE:XLE) as her final trade...
mRNA-1083 met its primary endpoints, eliciting higher immune responses against influenza virus and SARS-CoV-2 than licensed flu and COVID vaccines in adults 50 years and older, including an enhanced influenza vaccine in adults 65 years and older CAMBRIDGE, MA / ACCESSWIRE / June 10, 2024 / ...